U.S. Food and Drug Administration Investigating Cancer-Causing Chemicals in Metformin Diabetes Medications
Levels of doable cancer-causing chemical compounds in metformin diabetes medicines are underneath investigation by the U.S. Food and Drug Administration.
Through the previous year and a half, a number of types of medication—including angiotensin II receptor blockers and ranitidine (Zantac)—have been discovered to contain small amounts of genotoxic substances referred to as nitrosamines, such as N-nitrosodimethylamine (NDMA). Exposure to genotoxic substances above acceptable ranges over long periods might increase the risk for cancer, the FDA stated.
Food and Drug Administration has been inspecting the presence of nitrosamines in different drug products, and a few metformin diabetes medicines in different countries had been reported to have low levels of NDMA, in accordance with Janet Woodcock, M.D., director of the FDA Center for Drug Analysis and Research.
However, NDMA levels in metformin medication abroad are within the range that naturally happens in some foods and in water, she noted. Nonetheless, regulators in other countries are recalling certain metformin medicine, Woodcock stated. No metformin recollects have an effect on the U.S. market at the moment.
Woodcock stated the FDA is investigating whether or not metformin in the USA contains NDMA, and whether or not it exceeds the acceptable every day limit of 96 ng. “The agency may even work with companies to test samples of metformin sold within the U.S. and will recommend recalls as appropriate if high levels of NDMA are discovered,” Woodcock stated in an agency statement. “If, as a part of our investigation, metformin medication is recalled, the FDA will provide timely updates to patients and health care professionals.”